Aim: The effect of sacubitril-valsartan (ARNI) in heart failure (HF) patients with mid-range
ejection fractions (HFmrEF) remains unclear. This study aimed to investigate the effects of …

Angiotensin receptor–neprilysin inhibition has been shown to be superior to target doses of
an ACE inhibitor in reducing the risk of cardiovascular death and clinical disease …

Neprilisin and angiotensin receptor inhibition (Sacubitril/Valsartan, ie ARNI) is
recommended in heart failure guidelines for patients in NYHA class II-III with reduced left …

The development of the promising agent sacubitril/valsartan, known as an angiotensin
receptor blocker‐neprilysin inhibitor (ARNI), to improve heart failure (HF) management, may …

Heart failure is a term used to define a constellation of symptoms and signs that are
commonly attributed to the inability of the heart to produce a cardiac output that meets the …

The angiotensin receptor/neprilysin inhibitor Sacubitril/Valsartan (Sac/Val) has been shown
to be beneficial in patients suffering from heart failure with reduced ejection fraction (HFrEF) …

Aims Although the effect of the angiotensin receptor blocker neprilysin inhibitor (ARNI)
sacubitril/valsartan on heart failure (HF) hospitalizations and cardiovascular death has been …

Natriuretic peptides (NPs) promote diuresis, natriuresis and vasodilation in early chronic
heart failure (CHF), countering renin–angiotensin–aldosterone system (RAAS) and …

Background: Sacubitril/valsartan has been shown to be superior to enalapril in reducing the
risks of death and hospitalization for heart failure (HF). However, knowledge of the impact on …